Revance Releases Third Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Revance Therapeutics (RVNC) Misses Q3 EPS by 8c
November 2, 2017 4:53 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.01), $0.08 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $50 thousand.
2017 Financial Outlook
Revance reaffirmed its financial guidance provided in January 2017. Revance expects cash... More
